Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.70 |
| ▸ | FLT1 | P17948 | 6/20 | 0.70 |
| ▸ | PLK4 | O00444 | 1/20 | 0.70 |
| ▸ | AURKA | O14965 | 1/20 | 0.70 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.70 |
| ▸ | STK10 | O94804 | 1/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.70 |
| ▸ | ABL1 | P00519 | 1/20 | 0.70 |
| ▸ | EGFR | P00533 | 1/20 | 0.70 |
| ▸ | INSR | P06213 | 1/20 | 0.70 |
| ▸ | LCK | P06239 | 1/20 | 0.70 |
| ▸ | FYN | P06241 | 1/20 | 0.70 |
| ▸ | YES1 | P07947 | 1/20 | 0.70 |
| ▸ | LYN | P07948 | 1/20 | 0.70 |
| ▸ | RET | P07949 | 1/20 | 0.70 |
| ▸ | MET | P08581 | 1/20 | 0.70 |
| ▸ | ROS1 | P08922 | 1/20 | 0.70 |
| ▸ | BCR | P11274 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378810 | 0.92 | KDR (0.59) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL377871 | 0.92 | KDR (0.68) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL378227 | 0.92 | KDR (0.84) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL378621 | 0.91 | KDR (0.84) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL378726 | 0.91 | KDR (0.70) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL3078450 | 0.91 | KDR (0.66) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL3079528 | 0.90 | KDR (0.69) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL4845454 | 0.90 | KDR (0.69) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL378617 | 0.89 | KDR (0.56) | KDRPDGFRBFLT1PLK4AURKA | |
| SCHEMBL3081768 | 0.89 | KDR (0.72) | KDRPDGFRBFLT1PLK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884025-B2 | Processes for the preparation of isothiazole derivatives | PFIZER INC. | 2014-11-11 | — | — | US | claimed |
| EP-1784183-B1 | PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES | PFIZER (US) | 2012-01-25 | — | — | EP | claimed |
| EP-1545519-B1 | COMBINATION THERAPY FOR HYPERPROLIFERATIVE DISEASES | PFIZER (US) | 2011-03-23 | — | — | EP | claimed |
| US-20090023924-A1 | PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES | PFIZER INC. | 2009-01-22 | — | — | US | claimed |
| US-20070197517-A1 | Combination therapy for hyperproliferative disease | PFIZER INC. | 2007-08-23 | — | — | US | claimed |
| EP-1784183-A2 | PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES | Pfizer Products Incorporated (US) | 2007-05-16 | — | — | EP | claimed |
| WO-2006026034-A2 | PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2006-03-09 | — | — | WO | claimed |
| EP-1545519-A1 | COMBINATION THERAPY FOR HYPERPROLIFERATIVE DISEASES | Pfizer Products Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| EP-1084114-B1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2004017964-A1 | COMBINATION THERAPY FOR HYPERPROLIFERATIVE DISEASES | PFIZER PRODUCTS INC. (US) | 2004-03-04 | — | — | WO | claimed |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| US-6548526-B2 | Isothiazole derivatives useful as anticancer agents | PFIZER INC | 2003-04-15 | — | — | US | claimed |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | PFIZER, INC. | 2001-09-06 | — | — | US | claimed |
| EP-1084114-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| WO-1999062890-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-9371298-B2 | Processes for the preparation of isothiazole derivatives | PFIZER INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150065726-A1 | PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES | PFIZER INC. | 2015-03-05 | — | — | US | disclosed |
| US-6235764-B1 | Isothiazole derivatives useful as anticancer agents | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
| EP-1084114-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062890-A1 | ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023924-A1 | PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES | CYP3A4, CYP3A43, CYP2F1 | KDR 2551/4885PDGFRB 3219/4885FLT1 832/4885 |
| US-20010020034-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | KDR 2745/4885PDGFRB 3361/4885FLT1 1112/4885 |
| US-20150065726-A1 | PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES | CYP3A4, CYP3A43, CYP2F1 | KDR 2246/4885PDGFRB 3147/4885FLT1 849/4885 |
| US-20030149048-A1 | Isothiazole derivatives useful as anticancer agents | TP53, MCL1, ACIN1 | KDR 2745/4885PDGFRB 3361/4885FLT1 1112/4885 |
| US-20070197517-A1 | Combination therapy for hyperproliferative disease | TOP1, TOP2B, TOP2A | KDR 1127/4885PDGFRB 979/4885FLT1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.